North America Bacteriophages Therapy Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: North America Bacteriophages Therapy Market

North America Bacteriophages Therapy Market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.5% in the forecast period of 2021 to 2028 and is expected to reach USD 25.07 million by 2028. The increasing prevalence of antibiotic-resistant infections and technological advancements are the major drivers which propelled the demand of the market in the forecast period.  However, high costs associated with therapy and shortage of skilled professionals are the factors expected to restraint the market growth in the forecast period.

Bacteriophage, also called phage or bacterial virus, is any of a group of viruses that infect bacteria and are used to treat bacterial infections. This could be used as an alternative to antibiotics when bacteria develop resistance. Bacteriophages are much more specific than antibiotics. They are typically harmless not only to the host organism but also to other beneficial bacteria, such as the gut microbiota, reducing the chances of opportunistic infections. The presence of novel pipeline drugs, strategic initiatives by market players, and rise in expenditure in the healthcare sector is expected to provide a lucrative growth opportunity for the market.  However, the limitation of bacteriophage therapy and lack of proper regulatory guidelines acts as a major challenge in the growth of the market.  

The bacteriophages therapy market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal.

North America Bacteriophages Therapy Market Scope and Market Size

Bacteriophages therapy market is segmented on the basis of target, type, base, application, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets

• On the basis of target, North America bacteriophages therapy market is segmented into Escherichia coli, staphylococcus, streptococcus, pseudomonas, salmonella, others. In 2021 Staphylococcus segment is expected to dominate the market due to the rise in prevalence of staphylococcus infections and the rise in private and public funding.
• On the basis of type, North America bacteriophages therapy market is segmented into lytic and lysogenic. In 2021, the lytic segment is expected to dominate the market because of the specificity of action and narrow spectrum of activity.
• On the basis of the base, North America bacteriophages therapy market is segmented into sterile broth culture, water-soluble jelly base. In 2021, sterile broth culture is expected to dominate the market because it assesses living microbes and makes it easy to quantitate cells in the medium.
• On the basis of application, North America bacteriophages therapy market is segmented into bacterial dysentery, infections of the skin and nasal mucosa, suppurative skin infection, lung and pleural infections, post-operative wound infections, others. In 2021, the post-operative wound segment is expected to dominate the market due to the increasing number of surgeries such as cardiac surgeries, leg surgeries, among others, and an increasing number of road accidents leading to surgeries.
• On the basis of route of administration, the North America bacteriophages therapy market is segmented into oral, parenteral, rectal, dermal, others. In 2021, the oral segment is expected to dominate the market due to the ease and convenience of administration.
• On the basis of end-user, the North America bacteriophages therapy market is segmented into hospitals, specialty clinics, academic research & institutes, others. In 2021, the hospital's segment is expected to dominate the market due to increasing patient satisfaction and cost reduction.
• On the basis of distribution channel, the North America bacteriophages therapy market is segmented into direct sales and third-party distributors. In 2021, the direct tender segment is expected to dominate the market as it realizes cost-saving, and increases efficiency.

Bacteriophages Therapy Market Country Level Analysis

The bacteriophages therapy market is analyzed, and market size information is provided on the basis of target, type, base, application, route of administration, end-user, and distribution channel

The countries covered in the OCD drugs market report are the U.S., Canada, and Mexico.  

The lytic segment in the North America region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of the rise in research and development activities and increasing government funding. In North America, U.S is expected to dominate the market in the forecast period due to strongly established research infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Private Sector Funding And Technological Advancements Are Boosting The Market Growth Of Bacteriophages Therapy. 

Bacteriophages therapy market also provides you with detailed market analysis for every country growth in the bacteriophages therapy products industry with drugs sales, the impact of advancement, technology, and changes in regulatory scenarios with their support for the bacteriophages therapy market. The data is available for the historic period 2011 to 2019.

Competitive Landscape and Bacteriophages Therapy Market Share Analysis

Bacteriophages Therapy market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to OCD drugs market.

The major companies operating in the global bacteriophages therapy market are Microgen, Micreos, ATCC, INTRALYTIX, Adaptive Phage Therapeutics, Armata pharmaceuticals Inc., Locus Biosciences, INC., Delmont Laboratories, INC., Nextbiotics, Pherecydes Pharma, Pylum, iNTODEWORLD, INC., Enbiotix, Fixed-Phage Limited, and Cytophage Technologies Inc among others.

Many product launches and agreements are also initiated by companies worldwide, which are also accelerating the bacteriophage therapy market.

For instance,

• In April 2020, Phagelux, Inc. announced that the company has entered into multiple commercial collaborations such as European sales, marketing, and product development collaboration with DCM for its AgriPhage line of biopesticides, among others. This has helped the company to fully explore and develop next-generation bacteriophages

• In In July 2020, Intralytix, Inc. announced that the company had received a patent from the U.S. Patent and Trademark Office for its Shigella bacteriophages and its applications. The company further added that the patent covers various areas such as specific uses of these formulations, several bacteriophages with strong lytic potency against Shigella and their various formulations. This has helped the company to provide protection for a pre-determined period, allowing to keep competitors at bay
• In June 2021, Adaptive Phage Therapeutics announced the initiation of Phase 1/2 study of bacteriophage therapy (Phage Bank) to evaluate the safety, tolerability, and efficacy of targeted, personalized bacteriophage ("phage") treatments in patients with urinary tract infection (UTI).   This has helped the company to develop a novel treatment for multi multi-drug resistant bacterial infections.

Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player is enhancing the company market in the bacteriophage therapy market, which also provides the benefit for an organization to improve their offering for bacteriophage therapy.

SKU-65459